Biodistribution analysis of cisplatin in liposomal form in animals with cisplatin-resistant and cisplatin-sensitive carcinoma

Experimental Oncology

Volumn 32, Issue 1, 2010, Pages 40-43

  Nosko, M M ^a   Pivnyuk, V M ^a   Solyanik, G I ^a   Kulik, G I ^a   Todor, I N ^a   Momot, V Ya ^a   Melnikov, O R ^a   Ponomareva, O V ^a   Chekhun, V F ^a  

^a R E KAVETSKY INSTITUTE OF EXPERIMENTAL PATHOLOGY   (Ukraine)

Author keywords

Biodistribution; Cisplatin; Cisplatin resistance; Liposomal cisplatin; Pharmacokinetics

Indexed keywords

CISPLATIN; LIPOSOME;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; ATOMIC ABSORPTION SPECTROMETRY; CANCER RESISTANCE; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; FEMALE; GUERIN TUMOR; NONHUMAN; RAT; TUMOR VASCULARIZATION;

ANIMALS; ANTINEOPLASTIC AGENTS; BIOLOGICAL AVAILABILITY; CARCINOMA; CISPLATIN; DRUG RESISTANCE, NEOPLASM; FEMALE; LIPOSOMES; RATS; RATS, WISTAR; TISSUE DISTRIBUTION; TUMOR BURDEN;

EID: 77950581030     PISSN: 18129269     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Yurchenko OV, Todor IN, Tryndyak VP, et al. Resistance of Guerin carcinoma cells to cisplatin: biochemical and morphological aspects. Exp Oncol 2003; 25: 64-8 (In Russian).
2. Sharp SY, Rogers PM, Kelland LR. Transport of cisplatin and bis-acelato-ammine-dichlorocyclohexylamine platinum(IV) (JM216) in human ovarian carcinoma cell lines: identification of a plasma membrane protein associated with cisplatin resistance. Clin Cancer Res 1995; 1: 981-9.
3. Shen DW, Goldenberg S, Pastan I, et al. Decreased accumulation of [14C] carboplatin in human cisplatin-resistant cells results from reduced energy-dependent uptake. J Cell Physiol 2000; 183: 108-16.
4. Chekhun VF, Shishova YuV. Modern views on mechanism of formation of tumor drug resistance. Oncology 2000; 2: 11-5 (In Russian).
5. Desoize B, Madoulet C. Particular aspects of platinum compounds used at present in cancer treatment. Crit Rev Oncol/Hematol 2002; 42: 317-25.
6. Drummond DC, Meyer O, Hong K, et al. Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharmacol Rev 1999; 51: 691-743.
7. Immordino ML, Dosio F, Cattel L. Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential. Int J Nanomed 2006; 1: 297-315.
8. Urien S, Brain E, Bugat R, et al. Pharmacokinetics of platinum after oral or intravenous cisplatin: a phase 1 study in 32 adult patients. Cancer Chemother Pharmacol 2005; 55: 55-60.
9. Boulkas T. Low toxicity and anticancer activity of a novel liposomal cisplatin (Lipoplatin) in mouse xenografts. Oncol Rep 2004; 12: 3-12.
10. Wang S, Mi J-B, Li Y-Z, et al. Pharmacokinetics and tissue distribution of iv injection of polyphase liposomeencapsulated cisplatin (KM-1) in rats. Acta Pharmacol Sin 2003; 24: 589-92.
11. Zalipsky S, Saad M, Kiwan R, et al. Antitumor activity of new liposomal prodrug of mitomycin C in multidrug resistant solid tumor: insights of the mechanism of action. J Drug Target 2007; 15: 518-30.
12. Kulik GI, Pivnyuk VM, Nosko MM, et al. Liposomal preparations: a way to overcome drug resistance to cisplatin. Oncology 2009; 11: 76-80 (In Russian).
13. Nosko MM, Todor IN, Ponomareva OV, et al. Comparison of antitumor activity of cisplatin in free and liposomal forms in experiment. Ukr Med Almanakh 2008; 11: 114-5 (In Russian).
14. Khavesov I, Tsalev D. Atomic absorption analysis. Sophia: Chemistry, 1982; 141 p (In Russian).